A One-year, Phase III, Open-label, Non-comparative Trial of the Effect of Ziprasidone HCl on Metabolic Syndrome Risk Factors in Patients With Bipolar I Disorder.
Phase of Trial: Phase III
Latest Information Update: 06 Jul 2012
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 05 Apr 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 03 Mar 2011 Planned End Date changed from 1 Feb 2011 to 1 Jan 2011 as reported by ClinicalTrials.gov.